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Summary We report a case of fulminant myocarditis associated with N1H1 inﬂuenza virus
infection. N1H1 was conﬁrmed by a polymerase chain reaction assay and she was treated
with oseltamivir phosphate. She was admitted to the hospital because of respiratory distress,myocarditis;
Percutaneous
cardiopulmonary
support
however, echocardiography revealed severely depressed wall motion followed by refractory
ventricular ﬁbrillation. Extracorporeal circulation by emergent percutaneous cardiopulmonary
support system was required to maintain hemodynamic stability. Cardiac function was sponta-
neously and gradually restored within a week. Findings from biopsy samples taken on day 1 and
h acu
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A
mday 23 were consistent wit
© 2010 Japanese College o
ntroductionovel H1N1 inﬂuenza was ﬁrst detected in April 2009, and
as rapidly spread all over the world. While most people
ho have been sick have recovered without needing medical
reatment, hospitalizations and deaths have been reported.
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lthough not only respiratory but also myocardial involve-
ent has been suspected as the cause of sudden death,
here has been little information or case reports [1] con-
erning complications of fulminant myocarditis associated
ith this novel N1H1 inﬂuenza.ase report
previously healthy 44-year-old Japanese woman with a
istory of childhood asthma was brought to the emergency
oom on November 12, 2009 because of cough, dyspnea, and
Published by Elsevier Ireland Ltd. All rights reserved.
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reexamined. LVG showed near normal wall motion (Fig. 4).
Biopsies of myocardial tissue on day 1 showed slightly hyper-
trophied myocardium and edema and a relatively small
amount of inﬁltration of inﬂammatory cells. Biopsies on
day 23 showed some eosinophilic hypertrophied myocardiumFigure 1 Admission 1
fever. She went back home with a diagnosis of bronchitis.
She returned to the hospital because of severe respiratory
distress on the next day. On physical examination, con-
sciousness was alert, but she was covered with profuse
clammy sweat. The temperature was 38.3 ◦C, blood pres-
sure 89/40mmHg, pulse rate 120 beats per minute, and
the oxygen saturation, as measured by a cutaneous pulse
oxymeter was 94%. Chest examination revealed wheezing
without murmurs or pericardial friction rub. Laboratory
analysis showed metabolic acidosis and C-reactive protein
was elevated at 5.49mg/L. Level of electrolytes and liver
and renal function tests were normal. Although rapid test kit
for inﬂuenza was negative, the novel N1H1 inﬂuenza virus
DNA was conﬁrmed by polymerase chain reaction (PCR) anal-
ysis of tissue sections obtained from mucous membrane of
the nasal cavity. Electrocardiography on admission showed
sinus tachycardia and ST-segment depression of 2mm or
more in leads V2 through V6, II, III, and aVF (Fig. 1). On
November 13, ventricular ﬁbrillation (VF) occurred sud-
denly and was treated by electrical shock successfully.
Transthoracic echocardiography revealed severe hypokine-
sis with an estimated left ventricular ejection fraction
(LVEF) of 36%, without pericardial effusion and myocar-
dial edema. Cardiac catheterization and biopsy from the
right ventricular muscle tissue were performed. The car-
diac output was 3.78 L/min. Coronary angiography revealed
no organic lesions. Left ventriculogram (LVG) showed dif-
fuse severe hypokinesis and estimated ejection fraction
and left ventricular end-diastolic pressure was 23% and
22mmHg, respectively. Intra-aortic balloon pumping (IABP)
was placed after the examination for maintenance of hemo-
dynamics. Thirty-four hours after admission, VF developed
again (Fig. 2) Electrical shock was utterly ineffective. The
previously inserted femoral vein and artery sheath were
exchanged to 21F venous and 16F arterial cannula and
percutaneous cardiopulmonary support (PCPS) was setup
emergently. Initial ﬂow rate was 3.0 L/min. About 8min
after PCPS initiation, refractory VF resolved spontaneously.
When PCPS ﬂow was reduced from 2.0 to 1.5 L/min, fre-
quent ventricular premature beat recurred and oxygen
F
dad electrocardiogram.
aturation of central venous blood (SvO2) then dropped to
0%. Creatine kinase (CK) level was elevated to a maximum
f 2911 IU/L (CK-MB 112 IU/L). Ejection fraction recovered
rom 24% to 50% 3 days after PCPS initiation. The patient
as weaned off PCPS on day 5, and from IABP on day 8. She
ould leave the intensive care unit on day 14 (Fig. 3). The
eft ventricular wall thickness was 7mm on day 2. The wall
ecame edematous and increased to 12mm on day 13, this
igniﬁcantly improved to 8mm on day 22. QRS width was
2ms on day 2 and there were almost no changes through-
ut the entire clinical course. She did not develop any
onduction disturbance and lethal ventricular arrhythmias
ince then. On day 23, LVG and right ventricular biopsy wasigure 2 Electrocardiogram on November 14, 2009 her con-
ition took a sudden turn.
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Figure 3 Clinical course of the patient in the intensive care unit. Refractory ventricular ﬁbrillation (VF) occurred on the second
day in the hospital. Initial ﬂow of percutaneous cardiopulmonary support (PCPS) was 3 L/min. The patient was weaned off from
P day
L , dob
w
a
t
(
a
D
B
r
a
c
r
b
c
e
v
b
r
e
t
o
i
T
v
t
t
P
o
t
c
s
i
[
w
b
o
c
i
PCPS on day 5 and from intra-aortic balloon pumping (IABP) on
DH, lactic dehydrogenase; DOA, dopamine hydrochloride; DOB
ith exfoliation of myocardial ﬁbers, growth of chromatin,
nisokaryosis, and atrophy of myocardial cells. Inﬂamma-
ory cell inﬁltration on day 23 was less than that of day 1
Fig. 5). On December 16, 2009, the patient was discharged
nd returned to normal life.
iscussion
ased on the clinical course, myocardial biopsy, and PCR
esults, this case can be diagnosed as fulminant myocarditis
ssociated with novel N1H1 inﬂuenza virus [2].
Takotsubo cardiomyopathy was ruled out from the clinical
ourse. Eosinophilic myocarditis was also ruled out from the
esult of biopsy. The reason of eosinophilia (1120L) may
e affected by her allergic tendency. Continuous electro-
ardiographic (ECG) recording when she collapsed showed
levation prior to VT. This ECG change resembles that of
ariant angina pectoris. This was not completely ruled out
ecause we did not try spasm provocation test after she
ecovered, but the clinical course with no VT/Vf nor ST-
levation change and the fact that she recovered suggested
hat ECG change was solely due to myocarditis. The cause
2
t
t
m8. BP, blood pressure; CI, cardiac index; CK, creatine kinase;
utamine hydrochloride.
f fulminant myocarditis is commonly thought to be viral
nfection such as coxsackievirus, adenovirus, and so on.
he sensitivity of the neutralizing antibody of the causal
irus in the suspected viral myocarditis is very low, and
he exact prevalence of viral myocarditis is unknown. In
his case, novel N1H1 inﬂuenza virus was conﬁrmed by
CR assay and we could demonstrate the clinical course
f histopathology and myocardial functional recovery under
he support of extracorporeal circulation. There is no spe-
iﬁc therapy for fulminant myocarditis. Although one report
howed the advantageous effect of steroid and intravenous
njection of immunoglobulin for anti-inﬂammatory effect
3], these were not effective for many clinical cases. If
e had not used emergency PCPS, this patient would have
een diagnosed as sudden cardiac death. To the best of
ur knowledge, this is the ﬁrst report of the natural time-
ourse of fulminant myocarditis associated with novel N1H1
nﬂuenza in Japan. We rescued fulminant myocarditis by
CPS for the ﬁrst time in 1989 [4] and have experience of
0 similar cases in the past 20 years [4—8]. Characteris-
ic aspects of this case compared to previous cases were
hat ECG did not display ST-T elevation mimicking acute
yocardial infarction and inﬁltration of mononuclear cell
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Figure 4 Left ventriculogram in the right anterior oblique projection (RAO) on day 1 (a) and on day 23 (b).
opsy
r
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eFigure 5 Histopathology of right ventricular bi
was mild in the acute phase. The reason for ST-depression
on ECG but not ST-elevation may be that the inﬂammation
in this case was not transmural. However, the precise mech-
anism is unknown. According to myocardial biopsy on day
1, inﬂammatory change was mild. However, on the next
day after biopsy her condition abruptly got worse. This
discrepancy between the biopsy result and clinical course
may show that fulminant myocarditis can develop from
v
i
i
p
ispecimens taken on day 1 (a) and on day 23 (b).
eversible functional disorder by infection immunity. The
erious pump failure of fulminant myocarditis does not nec-
ssarily depend on destruction of cardiac muscle cell. The
entricular edematous thickness on day 13 may belong to
nﬂammation in the early phase. Left ventricular dysfunction
s more likely to recover in fulminant myocarditis, though
atients are more severely ill, than in acute myocardial
nfarction [5].
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In conclusion, we showed that novel N1H1 inﬂuenza can
e a cause of fulminant myocarditis and that cardiac func-
ion can be restored if the critical period is overcome by the
ssistance of extracorporeal circulation.
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